New search | Conferencedetail
Print view

6th Gene Therapy for Rare Disorders 2023

Evvnt Promotion / evvnt
20.03.2023 - 23.03.2023  Sheraton Boston Hotel, 39 Dalton St, 02199 Boston, USA
Time: 8:00 am to 5:00 pm
Conference themes
2022 has been a landmark year for the global gene therapy space. With August came the green light for bluebird bio's Zynteglo in the US, the first FDA approval for a gene therapy in over three years. Hot off its heels we saw the accelerated approval of another bluebird bio product, Skysona. Overseas, July and August brought EMA approvals for PTC Therapeutics' Upstaza and BioMarin's Roctavian, the first gene therapies for AADC deficiency and Haemophilia A respectively.
Scientific Society
Hanson Wade
Speakers: Faraz Ali, Chief Executive Officer, Tenaya Therapeutics, Deborah Ascheim, Chief Medical Officer, Stridebio, Eduard Ayuso, Chief Executive and Technology Officer, DiNAQOR, Sudha Babu, Regulatory CMC Leader, Spark Therapeutics and More

Enquiries and Registration:
Ms. Emily Birt
Health Services, Public Health
Congress fees
USD 2999.00 - USD 7095.00
Participants expected
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International promotes access to education and training for all regardless of social, geographic and national borders."

European Public Health Association (EUPHA)Hilfswerk AustriaEuropean Health Forum GasteinÖsterreichisches Rotes KreuzCharité International AcademyHelix - Forschung & Beratung WienÖsterreichische Akademie der ÄrzteÄrztekammer für Wien